Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Press

Showing results (221-230 of 273) with videos related to

Pageof 28
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 11, 2015
Reply to E.A. Rakha et alAntonio C Wolff, M Elizabeth H Hammond, David G Hicks, et al.
Molecular Cancer Therapeutics|November 5, 2016
HER2 Status in Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma for Entry to the TRIO-013/LOGiC Trial of LapatinibMichael F Press, Catherine E Ellis, Robert C Gagnon, et al.
Genome Medicine|May 7, 2026
African ancestry and risk variants associated with triple-negative breast cancer susceptibility in African American womenGuochong Jia, Lili Liu, Jie Ping, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 9, 2013
Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline updateAntonio C Wolff, M Elizabeth H Hammond, David G Hicks, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 3, 2015
Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III TrialJ Randolph Hecht, Yung-Jue Bang, Shukui K Qin, et al.
Archives of Pathology & Laboratory Medicine|October 9, 2013
Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline updateAntonio C Wolff, M Elizabeth H Hammond, David G Hicks, et al.
Human Genetics|July 6, 2016
Genetic variants in microRNA and microRNA biogenesis pathway genes and breast cancer risk among women of African ancestryFrank Qian, Ye Feng, Yonglan Zheng, et al.
Cancer Discovery|October 12, 2019
Circulating Tumor Cells Exhibit Metastatic Tropism and Reveal Brain Metastasis DriversRemi Klotz, Amal Thomas, Teng Teng, et al.
Nature Communications|November 18, 2020
Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07)Sara A Hurvitz, Jennifer L Caswell-Jin, Katherine L McNamara, et al.
Annals of Epidemiology|May 4, 2002
The NICHD Women's Contraceptive and Reproductive Experiences Study: methods and operational resultsPolly A Marchbanks, Jill A Mcdonald, Hoyt G Wilson, et al.
Pageof 28

Showing results (221-230 of 273) with videos related to

Sort By:
Pageof 28
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 11, 2015
Reply to E.A. Rakha et alAntonio C Wolff, M Elizabeth H Hammond, David G Hicks, et al.
Molecular Cancer Therapeutics|November 5, 2016
HER2 Status in Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma for Entry to the TRIO-013/LOGiC Trial of LapatinibMichael F Press, Catherine E Ellis, Robert C Gagnon, et al.
Genome Medicine|May 7, 2026
African ancestry and risk variants associated with triple-negative breast cancer susceptibility in African American womenGuochong Jia, Lili Liu, Jie Ping, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 9, 2013
Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline updateAntonio C Wolff, M Elizabeth H Hammond, David G Hicks, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 3, 2015
Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III TrialJ Randolph Hecht, Yung-Jue Bang, Shukui K Qin, et al.
Archives of Pathology & Laboratory Medicine|October 9, 2013
Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline updateAntonio C Wolff, M Elizabeth H Hammond, David G Hicks, et al.
Human Genetics|July 6, 2016
Genetic variants in microRNA and microRNA biogenesis pathway genes and breast cancer risk among women of African ancestryFrank Qian, Ye Feng, Yonglan Zheng, et al.
Cancer Discovery|October 12, 2019
Circulating Tumor Cells Exhibit Metastatic Tropism and Reveal Brain Metastasis DriversRemi Klotz, Amal Thomas, Teng Teng, et al.
Nature Communications|November 18, 2020
Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07)Sara A Hurvitz, Jennifer L Caswell-Jin, Katherine L McNamara, et al.
Annals of Epidemiology|May 4, 2002
The NICHD Women's Contraceptive and Reproductive Experiences Study: methods and operational resultsPolly A Marchbanks, Jill A Mcdonald, Hoyt G Wilson, et al.
Pageof 28